The Effects of a 50% Reduction of Cis(z)-Flupenthixol Decanoate in Chronic Schizophrenic Patients Maintained on a High Dose Regime
The DOI matches its Crossref record.
Abstract
Eighteen chronic schizophrenic patients who had shown improvement from increased maintenance dosages of cis(z)-flupenthixol decanoate were entered into a double-blind study in which half of the patients were randomly allocated to be maintained on 50% of their pre-trial dosage. During the 44 week study the reduced dosage group showed increased morbidity and one-third of these patients had a schizophrenic relapse. The greatest deterioration occurred in patients reduced from above to below 200 mg cis(z)-flupenthixol decanoate biweekly. A review of all the patients entered into the study showed a relationship between deterioration of schizophrenic and depressive features and cis(z)-flupenthixol plasma levels which reflected the administered dosage. Prolactin levels in general did not reflect control of schizophrenic symptoms. Side-effects were few, and there was no emergence of tardive dyskinesia. A multicentre trial is needed for further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
“The results have been inconsistent, with some reporting positive outcomes (Hogarty et al., 1988; Inderbitzin et al., 1994; Schooler et al., 1997) and others negative ones (Kane et al., 1983; Cookson, 1987; Johnson et al., 1987; Kreisman et al., 1988; Faraone et al., 1989).”
BackgroundResultBailey, L., & Taylor, D. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05311-2 · Cited by 21
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241272790 · Cited by 7
“…31 and t max32–34 information for the three decanoate-based LIDAs have been taken from existing literature, and pharmacokinetic studies for flupentixol decanoate, 35–37 haloperidol decanoate 33 and zuclopenthixol decanoate 32 were used to devise in silico models for plasma levels over time.”
Method
Metadata
- Authors
- COOKSON, I. B.
- Venue
- International Clinical Psychopharmacology
- Published
- 1987-04
- Volume
- 2
- Issue
- 2
- Pages
- 141-149
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2017574928
- Cited by
- 36
- References
- 0
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effects of a 50% Reduction of Cis(z)-Flupenthixol Decanoate in Chronic Schizophrenic Patients Maintained on a High Dose Regime. https://app.cochat.ai/papers/10.1097/00004850-198704000-00008
- The paper
- COOKSON, I. B. (1987). The Effects of a 50% Reduction of Cis(z)-Flupenthixol Decanoate in Chronic Schizophrenic Patients Maintained on a High Dose Regime. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-198704000-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.